Yonsei Med J.  2006 Apr;47(2):196-200. 10.3349/ymj.2006.47.2.196.

Plasma Factor XIII Activity in Patients with Disseminated Intravascular Coagulation

• Song JW
• Choi JR
• Song KS
• Rhee JH

• KMID: 1110742
• DOI: http://doi.org/10.3349/ymj.2006.47.2.196

Abstract

The objective of this study was to investigate the correlation between factor XIII (FXIII) activity and disseminated intravascular coagulation (DIC) parameters and also to evaluate the clinical usefulness of DIC diagnosis. Citrated plasma from eighty patients with potential DIC was analyzed for FXIII activity. The primary patient conditions (48 male and 32 female, mean age, 51 years) were malignancy (n = 29), infection (n = 25), inflammation (n = 6), heart disease (n= 3), thrombosis (n = 2), injury (n = 2), and other miscellaneous conditions (n = 13). FXIII testing was performed using the CoaLinkTM FXIII Incorporation Assay Kit (PeopleBio Inc.). Among 80 patients who were suspected to have DIC based on clinical analysis, 46 (57.5%) fulfilled the overt DIC criteria (DIC score > = 5) according to the International Society of Thrombosis and Haemostasis. FXIII levels in the plasma were significantly decreased in overt DIC compared to non-overt DIC patients (mean 75.1% and 199.7% respectively, p < 0.0001). Interestingly, we found a significant inverse correlation between DIC scores and FXIII activity. In addition, FXIII activity significantly correlated with other hemostatic markers that included platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer. FXIII levels were significantly lower in patients with liver or renal dysfunction. In conclusion, FXIII cross-linking activity measurements may have differential diagnostic value as well as predictive value in patients who are suspected to have DIC.

Keyword

Disseminated intravascular coagulation; factor XIII; hemostasis

MeSH Terms

Prothrombin Time
Platelet Count
Partial Thromboplastin Time
Middle Aged
Male
Liver Diseases/pathology
Liver/pathology
Kidney Diseases/pathology
Kidney/pathology
Inflammation
Humans
Hemostasis
Fibrin Fibrinogen Degradation Products/biosynthesis
Female
Factor XIII/*biosynthesis
Disseminated Intravascular Coagulation/*blood/*diagnosis
Cross-Linking Reagents/pharmacology/therapeutic use
Blood Coagulation Tests
Aged
Adult

Reference

1. Carell NA, Erickson HP, McDonagh J. Electron microscopy and hydrodynamic properties of factor XIII subunits. J Biol Chem. 1989. 264:551–556.

2. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991. 5:3071–3077.

3. Heinle K, Adam O, Rauh G. Factor XIII insufficiency in a patient with severe psoriasis vulgaris, arthritis, and infirmity. Clin Rheumatol. 1998. 17:346–348.

4. Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol. 2000. 54:260–266.

5. Egbring R, Kroniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost. 1996. 22:419–425.

6. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001. 86:1327–1330.

7. Ichinose A, Davie EW. Characterization of the gene for a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci USA. 1988. 85:5829–5833.

8. Sugimura D, Fukue H, Arai M, Matsumoto K, Fukutake K. Changes of factor XIII a and b subunit in patients with disseminated intravascular coagulation syndrome. Rinsho Byori. 1996. 44:355–361.

9. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999. 341:586–592.

10. Levi M, ten Cate H, van der Poll T, van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA. 1993. 270:975–979.

11. Heslet L. Cinical implications of a validated scoring system for disseminated intravascular coagulation. Crit Care Med. 2004. 32:2548–2549.

12. Delshammar M, Lasson A, Nilsson IM, Ohlsson K, Wallmark A, Vernersson E. Abnormal proteolysis (DIC)-Successful treatment with antithrombin III concentrate and a concentrate containing FXIII and native von Willebrand factor. J Intern Med. 1989. 225:21–27.

13. Ryo R, Sugano W, Yoshida A, Adachi M, Yasunaga M, Yoneda N, et al. Antiplasmin drugs and factor XIII concentrates in the treatment of a patient with acute promyelocytic leukemia(M3). Gan No Rinsho. 1989. 35:1479–1482.

14. Biland L, Duckert F, Prisender S, Nyman D. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost. 1978. 39:646–656.

15. Ballerini G, Guerra S, Rodeghiero F, Castaman G. A contribution to the pathology of acquired plasma factor XIII deficiency. Semin Thromb Hemost. 1985. 11:357–361.

16. Francis CW, Marder VJ. Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest. 1987. 80:1459–1465.